Dianthus Therapeutics, Inc. (DNTH)
$
42.11
+0.48 (1.14%)
Key metrics
Financial statements
Free cash flow per share
-2.9006
Market cap
1.5 Billion
Price to sales ratio
489.7647
Debt to equity
0.0024
Current ratio
17.3475
Income quality
0.8668
Average inventory
0
ROE
-0.3302
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for individuals affected by severe autoimmune and inflammatory diseases. The operating income ratio is -16.34 indicating the company's operational profitability margin. The EBITDA ratio is -16.27 highlighting the company's operational efficiency. The company reported selling, general, and administrative expenses of $24,994,000.00 indicating its operational overhead costs. The company's stock is identified with the symbol 'DNTH' in the market. Moreover, the diluted EPS is -$2.55 accounting for potential share dilution. Currently, the company is developing DNTH103, which is undergoing phase 1 clinical trials for conditions including generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Incorporated in 2015, Dianthus Therapeutics is based in New York, New York, and plays a vital role in the biotechnology sector. The stock is affordable at $36.75 suitable for budget-conscious investors. It has a low average trading volume of 652,280.00 indicating lower market activity. With a market capitalization of $1,524,877,382.00 the company is classified as a small-cap player. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field. The strategic focus on developing groundbreaking therapies for autoimmune and inflammatory diseases positions Dianthus Therapeutics as a promising candidate for investors seeking exposure to the biotechnology sector.
Is Dianthus Therapeutics, Inc. (DNTH) a good investment?
Investing in Dianthus Therapeutics, Inc. (DNTH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Dianthus Therapeutics, Inc. (DNTH)'s stock forecast?
Analysts predict Dianthus Therapeutics, Inc. stock to fluctuate between $13.37 (low) and $45.46 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Dianthus Therapeutics, Inc.'s market capitalization?
As of 2025-12-12, Dianthus Therapeutics, Inc.'s market cap is $1,524,877,382, based on 36,211,764 outstanding shares.
How does Dianthus Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Dianthus Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Dianthus Therapeutics, Inc. (DNTH) stock?
To buy Dianthus Therapeutics, Inc. (DNTH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DNTH. Place an order (Market, Limit, etc.).
What is the best time to invest in Dianthus Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Dianthus Therapeutics, Inc. stock ever split?
Dianthus Therapeutics, Inc.'s last stock split was 1:16 on 2023-09-12.
How did Dianthus Therapeutics, Inc. perform in the last earnings report?
Revenue: $6,235,000 | EPS: -$2.55 | Growth: -69.82%.
Where can I find Dianthus Therapeutics, Inc.'s investor relations reports?
Visit https://dianthustx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Dianthus Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Dianthus Therapeutics, Inc. stock?
All-time high: $45.46 (2025-12-04) | All-time low: $6.58 (2023-12-19).
What are the key trends affecting Dianthus Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.74 per share a year ago.
globenewswire.com
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing
globenewswire.com
NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“Dianthus” or the “Company”), today announced the pricing of its previously announced upsized underwritten public offering of 6,487,879 shares of its common stock at a public offering price per share of $33.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,112,121 shares of its common stock at a public offering price of $32.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering are expected to be approximately $251 million before deducting underwriting discounts and commissions and other offering expenses payable by Dianthus, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on September 11, 2025, subject to the satisfaction of customary closing conditions. In addition, Dianthus has granted the underwriters a 30-day option to purchase up to an additional 1,140,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by Dianthus.
seekingalpha.com
Dianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference Call Company Participants Marino Garcia - President, CEO & Director Simrat Randhawa - Chief Medical Officer Conference Call Participants Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Yaron Werber - TD Cowen, Research Division Myles Minter - William Blair & Company L.L.C., Research Division Presentation Operator Good morning, and welcome to the Dianthus Therapeutics Conference Call.
globenewswire.com
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT.
zacks.com
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago.
See all news
